Chelsie Derman

A study found individuals with type 2 diabetes who received less than 7 hours of sleep had 2.6 increased odds of microvascular disease.

Younger adults (aged 20 – 40 years) with OSA were 3 times more likely to experience any type of CVD event than those without OSA.

A new study showed the efficiency and speed of a new AI model for a heart scan.

A study with real-world data showed certolizumab pegol was effective in treating psoriasis a year later, with a probability of 1-year persistence at approximately 85%.

A new study confirms GLP-1RAs do not increase the risk for suicidal thoughts or behaviors, aligning with the FDA findings.

Individuals with both psoriasis and hypertension have approximately a 2-fold increased mortality risk, which is greater than the mortality risk for psoriasis or hypertension alone.

A study showed participants with symptoms of anxiety and depression had significantly fewer controlled cardiovascular disease risk factors.

Emerging treatments for CSA include hypochlorite phrenic nerve stimulation and pharmacological intervention, Badr told HCPLive.

Dunlop discusses what the next steps for MDMA-assisted therapy would be if approved.

Cook explains to HCPLive how elite athletes can optimize sleep for peak performance.

Dunlop provided his opinions on the committee’s comments regarding functional unblinding and cardiovascular implicative risks when it comes to studying MDMA.

Gozal told HCPLive about the issue of the classic approach when diagnosing children with OSA.

HCPLive spoke with Joshua M. Cohen, MD, MPH, to discuss a post-hoc analysis of a phase 3 study that showed buprenorphine may be effective at reducing fentanyl use.

This Month in Review spotlights interviews conducted at SLEEP 2024 and a recent FDA approval.

Family physician Scuderi shares how he helps patients manage PTSD symptoms ahead of Fourth of July fireworks.

This month in review captures the top FDA updates, including the first FDA Advisory Committee meeting to discuss the NDA for a psychedelic-assisted therapy.

FDA accepts a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, with a PDUFA date of February 8, 2025.

Machine learning outperformed clinical diagnostic criteria and the recommended screening criteria in the United Kingdom in identifying familial hypercholesterolemia.

A meta-analysis shows hand eczema has a moderate-to-severe impact on quality of life and anxiety.

FDA approves pitolisant for excessive daytime sleepiness and cataplexy in pediatric patients aged ≥ 6 years with narcolepsy.

Although AAT therapy was found to be well-tolerable, the infusions did not improve C-peptide AUC in patients with chronic pancreatitis undergoing TP-IAT.

The study APEX-002-B01-02 will evaluate how APEX-52, a microdose psilocybin, can impact safe driving.

A survey found individuals may avoid participating in AATD trials because a trial may require them to go off augmentation therapy.

Phase 3 data presented at EULAR found the biosimilar CT-P47 is similar to its reference product, tocilizumab, regarding efficacy, safety, and immunogenicity.

A phase 3 trial shows lumateperone as adjunctive therapy with antidepressants significantly reduces depression symptoms in patients with major depressive disorder.

After a biosimilar introduction, the prices of the biologic products—namely, trastuzumab, infliximab, bevacizumab, adalimumab, filgrastim, and pegfilgrastim—were significantly reduced.

Bourjeily told HCPLive at SLEEP 2024 that sleep issues, such as insomnia and restless legs syndrome, are the most common during the first and third trimester of pregnancy.

The first line treatment for restless legs syndrome—dopamine agonists—may be making a patient’s condition worse in the long-term, Winkelman told HCPLive at SLEEP 2024.

At SLEEP 2024, Kolla shared tips to help his fellow practitioners for improving patient outcomes when dealing with patients with both sleep issues and psychiatric illnesses.

Martin spoke about the barriers standing in the way of CPAP adherence in women with sleep apnea at SLEEP 2024.